GEN Exclusives

More »

GEN News Highlights

More »
Sep 11, 2008

bioMérieux Boosts Molecular Diagnostic Portfolio with Purchase of AviaraDx for $60M

  • bioMérieux acquired AviaraDx for $60 million expanding its portfolio of infectious disease molecular diagnostics to include tests that aid cancer management. The firm also gains AviaraDx’ CLIA-certified lab.

    AviaraDx will operate as an independent legal entity called bioTheranostics. The company has traditionally been focused on R&D with 19 employees and a limited sales team. bioMérieux reports that AviaraDx has had restricted sales and is projected to lose approximately $8 million this year. bioTheranostics is also predicted to have lower sales until 2012 and break even around that year.

    AviaraDx’ diagnostic tests are used to classify cancers on a molecular level to assist with prognosis. The company also has reportedly validated cancer biomarkers and capabilities in gene-expression profiling in tissues.

    Aviara CancerTYPE ID® provides cancer classification, especially for patients diagnosed with metastatic cancer where the origin is uncertain or unknown. Aviara Breast Cancer Index is used to evaluate two Aviara markers (H/I and MGI) for risk prognosis and treatment-response prediction for chemo and hormonal therapy.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?